You are currently viewing the abstract.View Full Text
This Podcast features an interview with Douglas Lauffenburger, author of a Research Article that appears in the 6 August 2013 issue of Science Signaling. In many types of cancers, cell growth is driven by changes in the activities of receptor tyrosine kinases (RTKs). Drugs that target RTKs are used to treat various cancers, but tumor cells often become resistant to the drugs and resume growth. By analyzing a public collection of data on cancer cell lines, Meyer et al. found that increased signaling by the receptor tyrosine kinase AXL predicts the development of resistance to inhibitors of the RTK ErbB. ErbB and AXL cooperated to promote cell migration in triple-negative breast cancer cells, suggesting that simultaneously inhibiting AXL and ErbB may be more effective than treating with ErbB inhibitors alone.